Last reviewed · How we verify
NCT05604664
Clinical Value and Efficacy Index of Lymphadenectomy for Thoracic Escc
trial in Esophageal Cancer in 1,727 participants. Completed in 10 October 2022.
1 October 2022
Quick facts
| Lead sponsor | Yongtao Han |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,727 |
| Start date | 1 May 2022 |
| Primary completion | 1 October 2022 |
| Estimated completion | 10 October 2022 |
| Sites | 1 location across China |
Conditions studied
- Esophageal Cancer — all drugs for Esophageal Cancer →
Sponsor
Yongtao Han — full company profile →
Who can join
Eligibility, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to to clarify the focus of lymph node dissection during esophagectomy.. The main question\[s\] it aims to answer is: * provide a basis for accurate staging and the relationship between OS and lymph node dissection
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05604664
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Esophageal Cancer
Currently open trials in the same condition.
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting
Other Yongtao Han trials
Trials by the same sponsor.
- NCT06169930 — Development and Validation of a Survival Prediction Model for Esophageal Cancer Patients After Esophagectomy · completed
- NCT05570487 — RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: AN OBSERVATIONAL STUDY · unknown
- NCT05617352 — The Impact of Two-field or Three-field Lymphadenectomy on Overall Survival in Middle and Lower Thoracic Esophageal Squam · completed
- NCT07236320 — Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC · NA · completed
- NCT06775652 — Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05604664 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yongtao Han
- Last refreshed: 4 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05604664.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing